How bad the reputation is depends on how much your in the red or if your short, heehee. I don't feel the way many here do, company should have been more conservative on cash or negotiated a larger upfront payment on deals (1 Billion in deals so far) but then I don't know the milestone structure. Advancing the science, has approval for the pet bone cancer treatment, and is less about 13 months away from EMA decision.
The shorts are responsible for the ridiculous valuation. Have seen it many times and it's a great buying opportunity.